Study on Clinical Application Monitoring of Monosialotetrahexosylganglioside Sodium Injection in Our Hospital / 中国药房

ABSTRACT

OBJECTIVE:To explore the general rules and characteristics of ADR/ADE induced by Monosialotetrahexosylgan-glioside sodium injection(GM1)as well as related risk factors,and to provide reference for safe,effective and economical drug use in clinic. METHODS:By hospital LAN,non-interventional centralized monitoring was conducted among patients receiving GM1 in our hospital from Jan.-Jun. 2016.The patients'information,drug use,ADR/ADE and clinical outcomes were analyzed sta-tistically. RESULTS:A total of 621 patients were involved,including 393 male patients and 228 female patients with male-to-fe-male ratio of 1.721.The patients who were more than 61 years old were the majority(60.39%).GM1 was mainly used in neurolo-gy department(71.18%),emergency department(6.28%),neurosurgery department(6.12%),general practice department(4.67%)and TCM rehabilitation department(4.03%). Among them,there were 28 ADR/ADE cases,with incidence of 4.51%. Among 42 patients with off-indication,3 cases had ADR/ADE,with incidence of 7.14%. Meanwhile,the constituent ratio of ADR/ADE in male(67.86%)was higher than that in female(32.14%). Twenty-two cases received more than three or more drugs(78.57%). Furthermore,ADR/ADE mainly manifested as systemic damage(35.71%),lesion of skin and its appendants (28.57%). Among 579 patients met drug use with indication,there were 165 cured cases,405 recovered cases and 9 uncured cases. In addition,the average expenditure of using GM1 was 5 108.08 yuan,accounting for 9.07% of total hospitalization cost and 23.33% of total drug cost. CONCLUSIONS:It is necessary to strengthen rational drug use and monitoring of GM1,under-stand the regularity and characteristics of GM1-induced ADR/ADE,so as to reduce the incidence of ADR/ADE and ensure safe, effective and economical drug use.